EXACT Sciences (NASDAQ:EXAS) is scheduled to be releasing its earnings data after the market closes on Thursday, February 22nd. Analysts expect EXACT Sciences to post earnings of ($0.29) per share for the quarter.
EXACT Sciences (EXAS) opened at $49.08 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. The firm has a market cap of $5,880.00, a PE ratio of -42.68 and a beta of 0.58. EXACT Sciences has a 52 week low of $18.50 and a 52 week high of $63.60.
In other EXACT Sciences news, insider Graham Peter Lidgard sold 45,770 shares of EXACT Sciences stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the completion of the sale, the insider now directly owns 237,820 shares in the company, valued at $13,857,771.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 764,182 shares of company stock valued at $40,574,047. 4.00% of the stock is owned by company insiders.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.